Bridging the Evidence Gap: Sotrovimab Use in Pregnancy and the Need for Comprehensive Drug Safety Data.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 841, doi. 10.1007/s40264-024-01457-x
- By:
- Publication type:
- Article
Works matching IS 01145916 AND DT 2024 AND VI 47 AND IP 9
Results: 10
1
2
Can We Ask ChatGPT About Drug Safety? Appropriateness of ChatGPT Responses to Questions About Drug Use and Adverse Reactions Received by Pharmacovigilance Centers.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 921, doi. 10.1007/s40264-024-01437-1
- By:
- Publication type:
- Article
3
Correction to: Sharing Adverse Drug Event Reports Between Hospitals and Community Pharmacists to Inform Re-dispensing: An Analysis of Reports and Process Outcomes.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
4
Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 909, doi. 10.1007/s40264-024-01443-3
- By:
- Publication type:
- Article
5
Key Opinion Leaders' Interviews to Inform the Future of Benefit–Risk Planning in the Medical Total Product Life Cycle of Global Pharmaceutical and Medical Device Organizations.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 853, doi. 10.1007/s40264-024-01442-4
- By:
- Publication type:
- Article
6
Use of Sotrovimab in Pregnancy: Experiences from the COVID-19 International Drug Pregnancy Registry.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 843, doi. 10.1007/s40264-024-01439-z
- By:
- Publication type:
- Article
7
Post-Conceptional Exposure to Clomiphene Citrate and Congenital Malformations: A Cohort Study.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 883, doi. 10.1007/s40264-024-01438-0
- By:
- Publication type:
- Article
8
Proceedings of the Canadian Medication Appropriateness and Deprescribing Network's 2023 National Meeting.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 829, doi. 10.1007/s40264-024-01444-2
- By:
- Publication type:
- Article
9
Targeting CCL24 in Inflammatory and Fibrotic Diseases: Rationale and Results from Three CM-101 Phase 1 Studies.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 869, doi. 10.1007/s40264-024-01436-2
- By:
- Publication type:
- Article
10
Timing Matters: A Machine Learning Method for the Prioritization of Drug–Drug Interactions Through Signal Detection in the FDA Adverse Event Reporting System and Their Relationship with Time of Co-exposure.
- Published in:
- Drug Safety, 2024, v. 47, n. 9, p. 895, doi. 10.1007/s40264-024-01430-8
- By:
- Publication type:
- Article